OrthoPediatrics’ (KIDS) Market Outperform Rating Reiterated at JMP Securities

OrthoPediatrics (NASDAQ:KIDS)‘s stock had its “market outperform” rating restated by equities researchers at JMP Securities in a research report issued on Tuesday, Benzinga reports. They presently have a $50.00 price target on the stock. JMP Securities’ price objective suggests a potential upside of 50.69% from the company’s previous close.

A number of other research analysts also recently issued reports on the stock. Truist Financial downgraded shares of OrthoPediatrics from a “buy” rating to a “hold” rating and reduced their price objective for the company from $39.00 to $31.00 in a research report on Thursday, January 25th. Needham & Company LLC reissued a “buy” rating and issued a $37.00 price target on shares of OrthoPediatrics in a research note on Wednesday, April 10th.

OrthoPediatrics Price Performance

Shares of OrthoPediatrics stock opened at $33.18 on Tuesday. The stock has a market capitalization of $789.35 million, a P/E ratio of -36.06 and a beta of 1.16. OrthoPediatrics has a one year low of $23.10 and a one year high of $48.47. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.44 and a quick ratio of 2.90. The business’s 50 day simple moving average is $28.91 and its two-hundred day simple moving average is $29.07.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.05. OrthoPediatrics had a negative net margin of 14.10% and a negative return on equity of 5.03%. The company had revenue of $37.61 million during the quarter, compared to analyst estimates of $37.59 million. Analysts forecast that OrthoPediatrics will post -1.34 EPS for the current year.

Insiders Place Their Bets

In other news, Director Mark C. Throdahl sold 2,433 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $27.59, for a total value of $67,126.47. Following the sale, the director now directly owns 137,857 shares of the company’s stock, valued at approximately $3,803,474.63. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other OrthoPediatrics news, Director Mark C. Throdahl sold 2,433 shares of OrthoPediatrics stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $27.59, for a total value of $67,126.47. Following the completion of the transaction, the director now directly owns 137,857 shares of the company’s stock, valued at $3,803,474.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joseph W. Hauser sold 2,903 shares of the stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $28.06, for a total value of $81,458.18. Following the sale, the insider now owns 52,858 shares in the company, valued at $1,483,195.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,253 shares of company stock worth $477,375. 31.80% of the stock is currently owned by company insiders.

Institutional Trading of OrthoPediatrics

A number of large investors have recently made changes to their positions in KIDS. Prime Capital Investment Advisors LLC bought a new stake in shares of OrthoPediatrics in the fourth quarter worth $2,035,000. Vanguard Group Inc. increased its holdings in OrthoPediatrics by 1.3% during the third quarter. Vanguard Group Inc. now owns 860,804 shares of the company’s stock valued at $27,546,000 after buying an additional 10,861 shares during the last quarter. Blue Trust Inc. raised its position in OrthoPediatrics by 1.5% in the fourth quarter. Blue Trust Inc. now owns 28,670 shares of the company’s stock worth $917,000 after acquiring an additional 421 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of OrthoPediatrics by 0.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,731 shares of the company’s stock valued at $3,895,000 after acquiring an additional 549 shares during the period. Finally, Conestoga Capital Advisors LLC lifted its position in OrthoPediatrics by 24.0% during the fourth quarter. Conestoga Capital Advisors LLC now owns 45,353 shares of the company’s stock valued at $1,474,000 after purchasing an additional 8,770 shares in the last quarter. 69.05% of the stock is currently owned by institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.